(Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States. The South San Francisco, ...

Maze Therapeutics is eyeing a $113 million initial public offering a little under two months after revealing a $115 million ...

Farmers gather across the UK in new protests over inheritance tax reforms - Rachel Hallos, a farmer and vice president of the ...

Step into a time machine and transport yourself back to the neon-soaked, pixelated world of the 1980s right in the heart of St. Paul, Minnesota. Starcade Classic Arcade is more than just a gaming ...